Medical Instruments & Supplies M&A » By The Online Investor Staff, updated Fri., Apr. 19, 4:03 AM
Recent mergers and acquisitions in the Medical Instruments & Supplies M&A category.
| This Slide: #34 of 100 |
Slide #34. Medtronic — TYRX, INC.
Acquirer:
Medtronic (NYSE:MDT)
Acquiree:
TYRX, INC.
Details:
Medtronic, Inc. (NYSE:MDT) today announced that it has acquired TYRX, Inc., a privately held, New Jersey-based developer of implantable combination antibiotic drug and implanted medical devices. TYRX's product offerings include the recently FDA cleared AIGISRx R Fully Resorbable Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs), and the AIGISRx N Antibacterial Envelope, for use with spinal cord neuromostimulators. The all cash transaction includes an initial payment of $160 million plus potential earn out and performance based milestone payments. Medtronic expects the net impact from this transaction to be neutral to fiscal year 2014 earnings and for this transaction to be consistent with the company's disciplined focus on long-term returns.
Medtronic is a medical technology, services and solutions company. Co.'s operating and reportable segments are as follows: Cardiovascular Portfolio, which is made up of the cardiac rhythm and heart failure, structural heart and aortic, and coronary and peripheral vascular divisions; Medical Surgical Portfolio, which is made up of the surgical innovations and respiratory, gastrointestinal, and renal divisions; Neuroscience Portfolio is made up of the cranial and spinal technologies, specialty therapies, and neuromodulation divisions; and Diabetes Operating Unit, which develops, manufactures, and markets products and services for the management of Type 1 and Type 2 diabetes.
Medtronic SEC Filing Email Alerts Service
Open the MDT Page at The Online Investor »
|
||||||||||||||||||||||||
Open the MDT Page at The Online Investor (in a new window) »
 Free MDT Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (2.76 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: MDT Stock Forecast Based on Zacks ABR data; powered by Xignite |
